Clinical trials: Unresectable Soft Tissue Sarcoma
Malignant Peripheral Nerve Sheath Tumors (MPNST), Sarcoma
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Phase 1: To assess the safety, tolerability, and maximum tolerated dose (MTD)/ recommended dose of ganetespib when administered in combination with sirolimus in patients with refractory or relapsed sarcomas including unresectable…
- Trial name
- NCT02008877
- Testing
- ganetespib, Sirolimus
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Fallopian Tube Cancer, Female Reproductive Cancer
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
This phase II trial is studying how well ziv-aflibercept works in treating patients with locally advanced, unresectable or metastatic gynecologic soft tissue sarcoma.
- Conditions
- Fallopian Tube Cancer, Female Reproductive Cancer, Ovarian Carcinosarcoma, Ovarian Sarcoma
- Trial name
- NCT00390234
- Testing
- ziv-aflibercept
- Where
- 16 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Cervical Cancer
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers
- Trial name
- NCT05812027
- Testing
- Tumor and HLA Profiling
- Where
- 21 sites in United States
- Volunteers
- 1,150 people
- Sponsor
- TScan Therapeutics, Inc.
Sarcoma, Soft Tissue
A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma
This is a single arm, open label, phase 2 study aimed to evaluate the efficacy and safety of the combination recombinant anti-PD-1 humanized monoclonal antibody injection (609A) and doxorubicin hydrochloride in the treatment of…
- Trial name
- NCT05138146
- Testing
- 609A, doxorubicin hydrochloride
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Adult Solid Neoplasm, Bladder Carcinoma
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
This phase I trial studies the side effects of vaccine therapy and pembrolizumab in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment, that…
- Conditions
- Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative
- Trial name
- NCT02432963
- Testing
- Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma
Niraparib for the Treatment of Leiomyosarcoma
This phase II trial tests whether niraparib works to shrink tumor in patients with leiomyosarcoma. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged.
- Conditions
- Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Stage III Retroperitoneal Sarcoma AJCC v8, Stage IIIA Retroperitoneal Sarcoma AJCC v8
- Trial name
- NCT05174455
- Testing
- Niraparib Tosylate Monohydrate
- Sponsor
- David Liebner, MD
Neoplasms
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.
- Trial name
- NCT05993299
- Testing
- Letetresgene autoleucel, Cyclophosphamide, Fludarabine
- Where
- 38 sites in United States, Canada and 5 more
- Volunteers
- 7 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
This is a phase 2b, randomized, open-label, prospective, multicenter study comparing treatment with INNO 206 to doxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas who have not been…
- Conditions
- Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
- Trial name
- NCT01514188
- Testing
- INNO-206, Doxorubicin
- Where
- 34 sites in United States, Australia and 5 more
- Volunteers
- 126 people
- Sponsor
- ImmunityBio, Inc.
Metastatic Colorectal Cancer (CRC)
A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation
This study is open to adults with advanced bowel cancer (colorectal cancer) with a KRAS mutation. This is a study in people for whom previous treatment was not successful and surgery is not a treatment option.
- Trial name
- NCT04627142
- Testing
- BI 1701963, Camptosar®
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
Bone Cancer, Chondrosarcoma
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
This phase II trial studies how well therapeutic angiotensin-(1-7) works as second-line therapy or third-line therapy in treating patients with metastatic sarcoma that cannot be removed by surgery.
- Conditions
- Bone Cancer, Chondrosarcoma, Clear Cell Sarcoma of the Kidney, Metastatic Osteosarcoma
- Trial name
- NCT01553539
- Testing
- therapeutic angiotensin-(1-7), laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Sarcoma, Soft Tissue
A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma
The main purpose of this study is to evaluate the efficacy and safety of recombinant anti-PD-1 humanized monoclonal antibody injection (609A) in patients with unresectable or advanced undifferentiated pleomorphic sarcoma
- Trial name
- NCT05193214
- Testing
- Recombinant anti-PD-1 humanized monoclonal antibody injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Sarcoma
Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma
To observe the effectiveness of SHR-1210 (Camrelizumab) combined with apatinib in the treatment of unresectable sarcoma patients with chemotherapy failure.
- Trial name
- NCT04126993
- Testing
- Camrelizumab,, Apatinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Sarcoma
Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have…
- Trial name
- NCT00017030
- Testing
- trabectedin
- Where
- 3 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
This phase I trial evaluates the safety and effectiveness of in situ immunomodulation with CDX-301, radiotherapy, CDX-1140 and Poly-ICLC (Cohort A) and these with intravenous (IV) pembrolizumab and subcutaneous (SC) tocilizumab…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Unresectable Breast Carcinoma
- Trial name
- NCT04616248
- Testing
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Southern California
Melanoma, Sarcoma
Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity
Hyperthermic isolated limb perfusion with melphalan alone is administered as a double perfusion schedule. These two isolates limb perfusions with melphalan are treated 3-6 weeks apart.
- Trial name
- NCT00001577
- Testing
- double isolated limb perfusion with melphalan alone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Progression-free Survival, Overall Survival
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma
Advanced soft tissue sarcoma patients who have previously recieved anthracyclines might still benefit from doxorubicin, ifosfamide and dacarbazine.
- Conditions
- Progression-free Survival, Overall Survival, Toxicity
- Trial name
- PDVPSTS (NCT03342300)
- Testing
- pegylated liposomal doxorubicin, pirarubicin
- Where
- China
- Sponsor
- Peking University People's Hospital
Pancreatic Cancer, Circulating Tumor DNA
CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer
With an incidence of more than 11,600 new cases per year in France and an annual number of deaths close to the incidence rate, adenocarcinoma of the pancreas is a public health problem.
- Conditions
- Pancreatic Cancer, Circulating Tumor DNA, KRAS Mutation-Related Tumors
- Trial name
- NCT04560270
- Testing
- Blood samples
- Volunteers
- 69 people
- Sponsor
- Poitiers University Hospital
Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor…
- Conditions
- Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation
- Trial name
- NCT03611868
- Testing
- Phase 1b: APG-115+pembrolizumab
- Where
- 21 sites in United States, Australia
- Volunteers
- 230 people
- Sponsor
- Ascentage Pharma Group Inc.
Soft Tissue Sarcomas
Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas
This trial will assess whether nivolumab alone or nivolumab combined with pazopanib will be associated with an improvement in progression free survival (PFS) at 6 months
- Trial name
- NCT03149120
- Testing
- Nivolumab, Pazopanib
- Where
- United States
- Sponsor
- NYU Langone Health